JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
Hong Kong
· Delayed Price · Currency is HKD 2.030
+0.130 (6.84%)
At close: Mar 10, 2026
HKG:2126 Revenue
JW (Cayman) Therapeutics Co. had revenue of 106.35M CNY in the half year ending June 30, 2025, with 21.21% growth. This brings the company's revenue in the last twelve months to 177.75M, up 2.79% year-over-year. In the year 2024, JW (Cayman) Therapeutics Co. had annual revenue of 158.22M, down -8.99%.
Revenue (ttm)
177.75M CNY
Revenue Growth
+2.79%
P/S Ratio
4.23
Revenue / Employee
608.73K CNY
Employees
292
Market Cap
823.45M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sirnaomics | 7.45M |
| Uni-Bio Science Group | 589.59M |
| 3D Medicines | 491.34M |
| Sunho Biologics | 18.63K |
| Brii Biosciences | 31.53M |
| Transcenta Holding | 10.31M |
| Wuhan YZY Biopharma | 163.65M |
| Beijing Biostar Pharmaceuticals | 58.66M |